Palvella Therapeutics, Inc. (PVLA) /
The cash flow of Palvella Therapeutics, Inc. over the past 10 years
Chart Palvella Therapeutics, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2023, Palvella Therapeutics, Inc.'s operating cash flow was -$13.7M and its capital expenditures $171K, leaving free cash flow of -$13.87M. Free cash flow was above zero in 1 of the 8 years shown. It ranged from -$60.97M in fiscal 2022 to $47.8M in fiscal 2017. Capital expenditures were highest in fiscal 2020, at $2.73M. No free cash flow figure is on file for fiscal 2024 and 2025.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$25.01M | — | — |
| 2024ended Dec 31, 2024 | -$10.84M | — | — |
| 2023ended Dec 31, 2023 | -$13.7M | $171K | -$13.87M |
| 2022ended Dec 31, 2022 | -$59.93M | $1.04M | -$60.97M |
| 2021ended Dec 31, 2021 | -$7.66M | $949K | -$8.61M |
| 2020ended Dec 31, 2020 | -$45.9M | $2.73M | -$48.62M |
| 2019ended Dec 31, 2019 | -$52.47M | $2.46M | -$54.93M |
| 2018ended Dec 31, 2018 | -$1.07M | $1.7M | -$2.76M |
| 2017ended Dec 31, 2017 | $49.75M | $1.95M | $47.8M |
| 2016ended Dec 31, 2016 | -$14.39M | $560K | -$14.95M |
Fiscal years as Palvella Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Palvella Therapeutics, Inc.
- The revenue of Palvella Therapeutics, Inc.
- The profitability of Palvella Therapeutics, Inc.
- The debt of Palvella Therapeutics, Inc.
- All of Palvella Therapeutics, Inc.'s financials, charted
Companies of a similar size
- NEOGNeogen Corporation
- PHINPHINIA INC.
- BBTBeacon Financial Corp
- WLYJOHN WILEY & SONS, INC.
- FCPTFour Corners Property Trust, Inc.
Not investment advice. This page shows what Palvella Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.